Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

1. Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT Full Text available with Trip Pro

Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404 (...) ) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Low-dose low-molecular-weight heparin was non-inferior in reducing venous thromboembolism events in surgical patients at medium or high risk compared with use of graduated compression stockings in addition to heparin. {{author}} {{($index

2020 NIHR HTA programme

2. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials

Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Thromb Res Actions . 2020 Jun 18;194:57-65. doi: 10.1016/j.thromres.2020.06.025. Online ahead of print. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials , , , , , , , , Affiliations Expand Affiliations 1 Hurley Medical Center, Department of Internal Medicine, Flint, MI, USA; Michigan State University, College of Human Medicine, East Lansing, MI, USA. 2 Lebanese University

2020 EvidenceUpdates

3. The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis

The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 May;120(5):832-846. doi: 10.1055/s-0040-1709712. Epub 2020 May 5. The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis , , , , , , , Affiliations Expand Affiliations 1 Clinical Epidemiology Program, Ottawa Hospital Research

2020 EvidenceUpdates

4. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children. (Abstract)

Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children. The prevalence of children diagnosed with thrombotic events has been increasing in the last decades. The most common thrombosis risk factor in neonates, infants and children is the placement of a central venous catheter (CVC). It is unknown if anticoagulation prophylaxis with low molecular weight heparin (LMWH) decreases CVC-related thrombosis in children. This is an update of the Cochrane (...) Review published in 2014.To determine the effect of LMWH prophylaxis on the incidence of CVC-related thrombosis and major and minor bleeding complications in children. Further objectives were to determine the effect of LMWH on occlusion of CVCs, number of days of CVC patency, episodes of catheter-related bloodstream infection (CRBSI), other side effects of LMWH (allergic reactions, abnormal coagulation profile, heparin-induced thrombocytopaenia and osteoporosis) and mortality during therapy.The

2020 Cochrane

5. Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT) Full Text available with Trip Pro

Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT) Combination of Two Complementary Automated Rapid Assays for Diagnosis of Heparin-Induced Thrombocytopenia (HIT) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Thromb Haemost Actions . 2020 Jun;18(6):1435-1446. doi: 10.1111/jth.14794. Epub 2020 Apr 27. Combination of Two Complementary Automated Rapid Assays for Diagnosis of Heparin-Induced Thrombocytopenia (HIT) , , , , , , Affiliations Expand Affiliations 1 Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. 2 Department of Medicine

2020 EvidenceUpdates

6. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. (Abstract)

Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Aspirin and heparin are widely used as preventive strategy to reduce the high risk of recurrent pregnancy loss in women with antiphospholipid antibodies (aPL). This review supersedes a previous, out-of-date review that evaluated all potential therapies for preventing recurrent pregnancy loss in women with aPL. The current review focusses on a narrower (...) scope because current clinical practice is restricted to using aspirin or heparins, or both for women with aPL in an attempt to reduce pregnancy complications.To assess the effects of aspirin or heparin, or both for improving pregnancy outcomes in women with persistent (on two separate occasions) aPL, either lupus anticoagulant (LAC), anticardiolipin (aCL) or aβ2-glycoprotein-I antibodies (aβ2GPI) or a combination, and recurrent pregnancy loss (two or more, which do not have to be consecutive).We

2020 Cochrane

7. Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long-term central venous catheters in infants and children. Full Text available with Trip Pro

Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long-term central venous catheters in infants and children. Guidelines and clinical practice for the prevention of complications associated with central venous catheters (CVC) around the world vary greatly. Most institutions recommend the use of heparin to prevent occlusion; there is debate, however, regarding the need for heparin and evidence to suggest normal saline (0.9% sodium (...) chloride) may be as effective. The use of heparin is not without risk, may be unnecessary and is also associated with increased cost. This is an update of the review published in 2015.To assess the clinical effects (benefits and harms) of intermittent flushing of normal saline versus heparin to prevent occlusion in long-term central venous catheters in infants and children.The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase

2020 Cochrane

8. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. (Abstract)

Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. The success of digital replantation is highly dependent on the patency of the repaired vessels after microvascular anastomosis. Antithrombotic agents are frequently used for preventing vascular occlusion. Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular surgery, but with fewer adverse effects. Its benefit in microvascular

2020 Cochrane

9. Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin

Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin March 2020 Jump to Resources Share By reading this page you agree (...) to ACOG's Terms and Conditions. . Baxter Healthcare first reported to the U.S. Food and Drug Administration in November 2017 shortages of heparin sodium 2,000 international units/L in 0.9% weight/volume sodium chloride intravenous infusion, heparin sodium 2,000 USP units in 1,000 mL, and heparin sodium 1,000 USP units in 500 mL . The purpose of this practice advisory is to review options for anticoagulation in late gestation for practitioners in areas affected by a heparin shortage. In some cases

2020 American College of Obstetricians and Gynecologists

10. Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization. (Abstract)

Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization. The role of cardiac catheterization in pediatrics has progressed significantly over the last two decades, evolving from a primary diagnostic tool to a primary treatment modality in children with congenital heart disease. Vascular complications, particularly arterial thrombosis, are among the most common unwanted post-cardiac catheterization events. In 1974, unfractionated (...) heparin proved to be superior to placebo in decreasing the incidence of arterial thrombosis in pediatric patients. However, the optimal dose of unfractionated heparin to be utilized in this setting remains a matter of controversy. This is an update of the review first published in 2014.To evaluate the use of low-dose (< 100 units/kg) versus high-dose (≥ 100 units/kg) unfractionated heparin administered as an intravenous bolus at the time of initiation of cardiac catheterization (that is, immediately

2020 Cochrane

11. Diagnosis and management of heparin?induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group

Diagnosis and management of heparin?induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range (...) to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group Joanne Joseph, David Rabbolini, Anoop K Enjeti, Emmanuel Favaloro, Marie‐Christine Kopp

2019 MJA Clinical Guidelines

12. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Full Text available with Trip Pro

Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. This an update of the review first published in 2009.Major abdominal and pelvic surgery carries a high risk of venous thromboembolism (VTE). The efficacy of thromboprophylaxis with low molecular weight heparin (LMWH) administered during the in-hospital period is well-documented, but the optimal duration of prophylaxis after surgery remains controversial. Some studies suggest that patients undergoing

2019 Cochrane

13. Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial. (Abstract)

Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial. Management of anticoagulants for patients undergoing polypectomy is still controversial. Cold snare polypectomy (CSP) is reported to cause less bleeding than hot snare polypectomy (HSP).To compare outcomes between continuous administration of anticoagulants (CA) with CSP (CA+CSP) and periprocedural heparin

2019 Annals of Internal Medicine Controlled trial quality: predicted high

14. Occlusion between heparin saline and 0.9% sodium chloride in adults: A Snapshot

Occlusion between heparin saline and 0.9% sodium chloride in adults: A Snapshot Heparin versus saline and occlusion in adults: A Snapshot 1 Occlusion between heparin saline and 0.9% sodium chloride in adults: A Snapshot Citation Corey Joseph & Angela Melder. August 2018. Occlusion between heparin saline and 0.9% sodium chloride in adults: A Snapshot. Centre for Clinical Effectiveness, Monash Health, Melbourne, Australia. Executive Summary Background The Centre for Clinical Effectiveness have (...) patency between heparinised saline and 0.9% Sodium Chloride solution in Adults. Specifically, the review will focus on central lines only. Findings ? Given the very low-quality of the evidence, it is uncertain whether heparin saline results in fewer occlusions than normal saline. 3,4 ? Low quality evidence suggests there is no difference in occlusion of line access, lumen and patient between heparin saline and normal saline. 4 ? In the short term ( 30 days) there was not difference in occlusion

2019 Monash Health Evidence Reviews

15. Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned GPI during primary percutaneous coronary intervention in acute myocardial infarction - a VALIDATE-SWEDEHEART substudy (Abstract)

Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned GPI during primary percutaneous coronary intervention in acute myocardial infarction - a VALIDATE-SWEDEHEART substudy Heparin is the preferred choice of anticoagulant in percutaneous coronary intervention (PCI) for acute myocardial infarction (MI). An established dosage of heparin has not yet been determined, but treatment may be optimized through monitoring (...) of activating clotting time (ACT). The aim of this study was to determine the relationship between heparin dose or ACT with a composite outcome of death, MI or bleeding using data from the registry-based, randomized, controlled and open-label VALIDATE-SWEDEHEART-trial, although patients were not randomized to heparin dose in this sub-study.Patients with MI undergoing PCI and receiving treatment with a potent P2Y12-inhibitor and anticoagulation with heparin, without the planned use of glycoprotein IIb/IIIa

2019 European heart journal. Cardiovascular pharmacotherapy Controlled trial quality: uncertain

16. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia Full Text available with Trip Pro

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism.These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care (...) thromboembolism prophylaxis.Strong recommendations include use of the 4Ts score rather than a gestalt approach for estimating the pretest probability of HIT and avoidance of HIT laboratory testing and empiric treatment of HIT in patients with a low-probability 4Ts score. Conditional recommendations include the choice among non-heparin anticoagulants (argatroban, bivalirudin, danaparoid, fondaparinux, direct oral anticoagulants) for treatment of acute HIT.© 2018 by The American Society of Hematology.

2018 Blood advances

17. Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia Full Text available with Trip Pro

Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia The HIT Expert Probability (HEP) score compared favorably with the 4Ts score in a retrospective study. We assessed the diagnostic accuracy of the HEP score compared with the 4Ts score in a prospective cohort of 310 patients with suspected heparin-induced thrombocytopenia (HIT). A member of the clinical team calculated the HEP score and 4Ts score. An independent panel adjudicated HIT

2018 Blood advances

18. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial Full Text available with Trip Pro

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous

2018 EvidenceUpdates

19. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. (Abstract)

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional (...) coronary angiography to radial or femoral access and to bivalirudin, with or without post-percutaneous coronary intervention infusion or unfractionated heparin (one-step inclusion). Patients with non-ST-elevation acute coronary syndrome were randomly assigned (1:1) before coronary angiography to radial or femoral access and, only if deemed eligible to percutaneous coronary intervention after angiography (two-step inclusion), entered the antithrombin type and treatment duration programmes. Randomisation

2018 Lancet Controlled trial quality: predicted high

20. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors Full Text available with Trip Pro

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors Anticoagulants such as unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), fondaparinux, and direct oral anticoagulants (DOACs) targeting thrombin (IIa) or factor Xa (FXa) are widely used in prevention and treatment of thromboembolic disorders. However, anticoagulant-associated bleeding is a concern that demands monitoring and neutralization. Protamine (...) , the UFH antidote, has limitations, while there is no antidote available for certain direct FXa inhibitors. Improved antidotes in development include UHRA (Universal Heparin Reversal Agent) for all heparin anticoagulants; andexanet alfa (andexanet), a recombinant antidote for both direct FXa inhibitors and LMWHs; and ciraparantag (PER977), a small-molecule antidote for UFH, LMWHs, and certain DOACs. The binding affinities of these antidotes for their presumed anticoagulant targets have not been

2018 Blood advances